Oppenheimer Maintains an 'Outperform' on Curis (CRIS); Good Q2, Now Milestones Become Focus
Tweet Send to a FriendGet Alerts CRIS Hot Sheet
Price: $3.89 +0.26%
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Trade CRIS Now!
Oppenheimer maintains an 'Outperform' on Curis (NASDAQ: CRIS) price target of $5.50.
Analyst, Boris Peaker, said, "Curis reported 2Q12 results consistent with expectations and inclusive of the previously announced milestone. Erivedge revenues/royalties were roughly flat with 1Q, as stocking likely worked through the system. We maintain our recently revised Erivedge ramp expectations and caution that while we are bullish on the long-term outlook for the drug, near-term growth could remain lumpy as docs gain comfort. In 2H12/1H13 the primary catalysts for Curis are milestone-driven. We highlight the potential for Erivedge approval in the EU in late-'12/early-'13 and Australian approval in 1H13. Results are also expected from the CUDC-101 study in head and neck cancer and Erivedge operable BCC."
FY13 EPS estimate lowered from (0.25) to (0.26)
For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.
Shares of Curis closed at $4.63 yesterday, with a 52 week range of $2.70-$5.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Boris Peaker, said, "Curis reported 2Q12 results consistent with expectations and inclusive of the previously announced milestone. Erivedge revenues/royalties were roughly flat with 1Q, as stocking likely worked through the system. We maintain our recently revised Erivedge ramp expectations and caution that while we are bullish on the long-term outlook for the drug, near-term growth could remain lumpy as docs gain comfort. In 2H12/1H13 the primary catalysts for Curis are milestone-driven. We highlight the potential for Erivedge approval in the EU in late-'12/early-'13 and Australian approval in 1H13. Results are also expected from the CUDC-101 study in head and neck cancer and Erivedge operable BCC."
FY13 EPS estimate lowered from (0.25) to (0.26)
For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.
Shares of Curis closed at $4.63 yesterday, with a 52 week range of $2.70-$5.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Benchmark Boosts PT on R.R. Donnelley (RRD)
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- Best Buy (BBY) Numbers Raised at Jefferies Post Q1
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
